Aspira Women's Health INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
John Strahley, Chief Financial Officer of Aspira Women's Health Inc., received 70,000 shares of common stock on June 16, 2026.
John Strahley, Chief Financial Officer of Aspira Women's Health Inc., received 75,000 shares of common stock on June 16, 2026.
Director and 10% owner Jack W. Schuler acquired 222,222 shares and 300,000 warrants of Aspira Women's Health Inc. in a recent transaction.
Director Jeffrey Cohen acquired 11,112 shares of Aspira Women's Health Inc. common stock through a property settlement.
Aspira Women's Health Director Cynthia D. Hundorfean acquired 238,085 stock options with an exercise price of $0.35.
Aspira Women's Health Inc. Director John D. Fraser received a grant of 314,811 stock options with an exercise price of $0.35.
Aspira Women's Health Director Jane Pine Wood acquired 135,592 stock options with an exercise price of $0.35, exercisable immediately.
Aspira Women's Health Director Winfred Parnell acquired 185,178 stock options with an exercise price of $0.35.
Aspira Women's Health Inc. Director Jeffrey K. Cohen has pre-scheduled the acquisition of 213,518 stock options with an exercise price of $0.35, effective December 2, 2025, under a Rule 10b5-1 plan.
Aspira Women's Health Inc. Director Ellen Beausang acquired 198,097 stock options at an exercise price of $0.35, exercisable immediately.
Aspira Women's Health Director and 10% Owner Jack W. Schuler acquired over 1.1 million shares and 833,333 warrants through his living trust.
Aspira Women's Health Director Jeffrey Cohen acquired additional common stock and warrants, increasing his beneficial ownership.
Aspira Women's Health Director John D. Fraser increased his direct and indirect holdings through open market purchases of common stock and warrants.
Aspira Women's Health Inc. Chief Financial Officer Brian Hungerford received a grant of 100,000 employee stock options with an exercise price of $0.41.
Ellen O'Connor Vos, a Director at Aspira Women's Health Inc., has converted 5,312 restricted stock units (RSUs) into common stock following their vesting on June 4, 2025.
Aspira Women's Health Inc. Director John Phillip Ragard converted 4,844 restricted stock units into common stock following their vesting on June 4, 2025, increasing his direct beneficial ownership to 134,734 shares.
Aspira Women's Health Inc. Director Stefanie L. Cavanaugh has converted 5,937 restricted stock units (RSUs) into common stock following their vesting on June 4, 2025.
Aspira Women's Health Inc. Director Jannie Herchuk converted 8,437 vested restricted stock units into common stock on June 4, 2025, increasing her direct beneficial ownership to 82,502 shares.
Aspira Women's Health Inc. Director Winfred Parnell acquired 5,156 shares of common stock through the vesting and conversion of restricted stock units on June 4, 2025.
Aspira Women's Health Inc. Director Ellen Beausang has converted 4,843 restricted stock units into common stock following their vesting on June 4, 2025.
Form 4: Aspira Women's Health Director Jeffrey Cohen Increases Stake Through Spouse's Stock Acquisitions
Aspira Women's Health Inc. Director Jeffrey Cohen reported two recent acquisitions of common stock by his spouse, increasing his indirect beneficial ownership in the company.
Aspira Women's Health Inc. CEO, Michael William Buhle, was granted 100,000 stock options with an exercise price of $0.07, vesting monthly over four years.
Director Ellen O'Connor Vos converted 5,313 restricted stock units into common stock of Aspira Women's Health Inc. on March 31, 2025.
Director Winfred Parnell of Aspira Women's Health Inc. reports the vesting and conversion of restricted stock units into common stock on March 31, 2025.
Director Ellen Beausang converted 1,615 restricted stock units into common stock of Aspira Women's Health Inc. on March 31, 2025.
Director Ellen Beausang acquired 6,458 restricted stock units of Aspira Women's Health Inc. on March 11, 2025.
Director Stefanie L. Cavanaugh of Aspira Women's Health Inc. reports the vesting and conversion of restricted stock units into common stock.
Director John Phillip Ragard converted 4,843 restricted stock units into common stock of Aspira Women's Health Inc. on March 31, 2025.
Director Jannie Prestridge Herchuk converted 8,438 restricted stock units into common stock of Aspira Women's Health Inc. on March 31, 2025.
Director Celeste Rachelle Fralick reports the conversion of restricted stock units into common stock of Aspira Women's Health Inc.